GlassScriptPhysician profile
Lindsey Barton Mosley
NPI 1861086753
$4,937.16
in general payments reported to CMS, 2019-2025
31 companies · $1,026 in 2025
The $1,026 reported for 2025 was more than what 96% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $253 · 2022: $980 · 2023: $1,272 · 2024: $1,407 · 2025: $1,026.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,705.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,704.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $938.97 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $380.58 | 2023-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $344.75 | 2022-2025 | Veozah, Myrbetriq |
| Mayne Pharma Commercial LLC | $339.11 | 2022-2025 | |
| Pfizer INC. | $288.90 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $272.88 | 2023-2025 | |
| Novo Nordisk INC | $234.45 | 2023-2025 | Wegovy |
| Exact Sciences Corporation | $211.24 | 2023-2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $205.86 | 2023-2024 | Quviviq |
| Cosette Pharmaceuticals INC. | $191.73 | 2025 | Vyleesi |
| Myovant Sciences INC. | $158.31 | 2021-2022 | |
| Organon LLC | $138.36 | 2021-2025 | Nexplanon |
| Lilly USA, LLC | $138.24 | 2023-2025 | Zepbound, Mounjaro |
| Ascend Therapeutics US, LLC | $119.51 | 2022 | |
| Hologic Sales and Service, LLC | $119.44 | 2022-2025 | Myosure Tissue Removal Device, Aptima, Thinprep 2000 Processor |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $119.12 | 2022-2025 | Slynd |
| Millicent US INC | $107.65 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Shield Therapeutics INC | $94.31 | 2023-2024 | Accrufer |
| Vivus LLC | $77.69 | 2024-2025 | Pancreaze |
| Mycovia Pharmaceuticals, INC. | $74.76 | 2022-2023 | Vivjoa |
| Scynexis, INC. | $71.56 | 2022 | |
| Mylan Pharmaceuticals INC. | $65.82 | 2022 | |
| Avion Pharmaceuticals | $57.22 | 2022 | |
| Evofem Biosciences, INC. | $35.56 | 2022 | |
| Aspira Women'S Health INC | $30.82 | 2023-2024 | Ova1 |
| Tactile Systems Technology INC | $26.54 | 2022 | |
| Sage Therapeutics, LLC | $22.01 | 2024 | |
| Merck Sharp & Dohme LLC | $19.39 | 2024 | Gardasil, Gardasil 9 |
| Coopersurgical, INC. | $19.31 | 2023 | Paragard T 380a |
| Janssen Pharmaceuticals, INC | $17.68 | 2023 | Spravato |
| Amgen INC. | $15.39 | 2024 | Evenity, Prolia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Mosley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.